Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

65.56 -0.68 (-1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with... 
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
 
Via Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
The company passed investors' bar for success in a study of a head-and-neck cancer treatment. 
Via Investor's Business Daily
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! 
Via InvestorPlace
Expert Ratings for Merus
 
Via Benzinga
The Latest Analyst Ratings for Merus
 
Via Benzinga
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
From Merus N.V.
Via GlobeNewswire
MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024
MRUS stock results show that Merus beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
If approved, Zeno will be the first targeted therapy for NRG1+ cancer 
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
From Gilead Sciences, Inc.
Via Business Wire
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT 
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
From Merus N.V.
Via GlobeNewswire
Merus Announces Business Update Conference Call
From Merus N.V.
Via GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.